Results 151 to 160 of about 2,835 (171)

Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Florineth GA, Klima I, Boeker AL, Catzeflis P, Wopfner A, Denier N, Bracht T, Adorjan K, Pfammatter M, Müller F, Soravia LM.   +10 more
europepmc   +1 more source

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.

JAMA Netw Open
Yngwe H, Plavén-Sigray P, Ekman CJ, Henje E, Berglund A, Tiger M, Beckman M, Lundberg J.   +7 more
europepmc   +1 more source

Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis

Journal of Humanistic Psychology, 2017
The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy.
Alexander B Belser, Gabrielle Agin-Liebes, Sara Terrana   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy

American Journal of Psychotherapy, 2021
This systematized review sought to fill a gap in psilocybin research by investigating the structure and format of psilocybin-assisted psychotherapy (PAP), with a focus on the counseling components of the treatment.A systematized review of PAP was conducted by using the PubMed and PsycInfo databases to search for peer-reviewed studies of human clinical ...
David M, Horton, Blaise, Morrison, Judy, Schmidt   +2 more
exaly   +3 more sources

The safety of psilocybin-assisted psychotherapy: A systematic review

Australian & New Zealand Journal of Psychiatry
Introduction: Psilocybin, a classical psychedelic, has been rescheduled for use in psilocybin-assisted psychotherapy for treatment-resistant depression in Australia. While evidence for its use is promising, understanding the associated risks is crucial. Accordingly, this review aims to collate adverse event data
Rosana R Freitas, Efstathia S Gotsis, Alexander T Gallo, Bernadette M Fitzgibbon, Neil W Bailey, Paul B Fitzgerald   +5 more
openaire   +3 more sources

Longitudinal Impacts of Psilocybin-Assisted-Psychotherapy on Depression

, 2023
This study investigates the long-term impact of psilocybin-assisted psychotherapy (PAP) on depression symptoms in individuals with major depressive disorder. The study will recruit 40 adults aged 18 years and older, diagnosed with major depressive disorder and who have failed to respond to at least one antidepressant medication in the past ...
Blake Altamirano
openaire   +2 more sources

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review

Journal of Psychiatric Research
Psilocybin-assisted psychotherapy (PAP) is a promising treatment option for depression, with randomized controlled trials (RCTs) providing preliminary support for its safety and efficacy. However, there is a lack of consistency across existing treatment protocols and psychotherapeutic approaches. The objective of this review is to summarize and compare
Noah Chisamore, Wanming Chen, Zoe Doyle   +2 more
exaly   +3 more sources

Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress

Journal of Humanistic Psychology, 2017
Recent randomized controlled trials of psilocybin-assisted psychotherapy for patients with cancer suggest that this treatment results in large-magnitude reductions in anxiety and depression as well as improvements in attitudes toward disease progression
Alexander B Belser, Gabrielle Agin-Liebes, Sara Terrana   +2 more
exaly   +2 more sources

Psilocybin-Assisted Psychotherapy in Palliative Care

2022
AbstractFollowing a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic therapeutics to alleviate the marked psychic distress in end-of-life cancer patients, major academic centers are resuming contemporary clinical research into the safety and efficacy of psilocybin and other ...
Stephen Ross, Anthony P. Bossis
openaire   +1 more source